Coronavirus

Intranasal Covid-19 vaccine production commences at Pune’s Serum Institute of India

Last updated on February 17th, 2023 at 01:04 pm

 Intranasal vaccine for Covid-19 virus SARS-CoV-2 is not under any clinical trial currently, but Serum Institute of India has started production of an intranasal vaccine candidate, informed Union Health Minister Dr. Harsh Vardhan on Monday. Various Covid-19 vaccine candidates are currently under human trials in India.

Dr. Harsh Vardhan said, “Flumist nasal spray is a vaccine that is sprayed into the nose to help protest against influenza; it is not a Covid-19 vaccine. At present in India, there is no intranasal Covid vaccine which is under clinical trials. However, Serum Institute of India has begun manufacturing Codagenix CDX 005, which is an intranasal live attenuated vaccine candidate for Sars-Cov-2.”

The phase 1 trials will take place in the US in St. Louis University’s vaccine and treatment evaluation unit, on getting regulatory approval, Bharat Biotech will pursue further stages of clinical trials in India

Dr. Harsh Vardhan

“Pre-clinical animal studies have already been completed and Codagenix expects to initiate a phase 1 clinical first in humans trial in the United Kingdom by the end of 2020. Further, Serum India plans to undertake clinical developments of this vaccine candidate in India,” he added.

As a part of the sixth episode of Sunday Samvaad, the Minister was responding to the questions on his social media accounts.  He relayed that India’s Bharat Biotech has also signed an agreement with Washington University School of Medicine. Through this trials will be conducted to produce and market an intranasal vaccine for Covid-19.

“The phase 1 trials will take place in the US in St. Louis University’s vaccine and treatment evaluation unit, on getting regulatory approval, Bharat Biotech will pursue further stages of clinical trials in India,” he said.

Dr. Harsh Vardhan said that Bharat Biotech’s vaccine candidate was being tested on people between 18 and 55 years in phase 1, and for phase 2, it was extended to include participants of ages between 12 and 65 years.

Read: “Sindhu was not happy with the training in national camp”: PV Raman, Sindhu’s father

CV Journalist

Dr. Neha Mathur, a distinguished member of the India Observers team, specializes in Health and Wellness. With a profound commitment to keeping our readers informed, Dr. Neha shares expert insights on health-related topics. Navigate the world of well-being with Dr. Neha's expertise and dedication to your health journey.

Recent Posts

Landmark Verdict of SC over the private properties in Article 39(b)

Since 1977, the verdict which states that both public and private resources can be taken…

November 5, 2024

Modi Censured Violence After Canada Temple Incident

The dubious video which has been uploaded on social media became viral in which the…

November 5, 2024

PM Modi Campaign “Roti, Beti, Maati ki pukar” Vision in Jharkhand’s Garhwa

On Monday Prime Minister Narendra Modi stated that Jharkhand polls are taking place while the…

November 4, 2024

Bollywood’s Diwali Blockbusters: Bhool Bhulaiyaa 3 and Singham Again Cross ₹200 Crore Combined Weekend Collection

An unprecedented battle occurred during the Diwali weekend at the box office in which Bhool…

November 4, 2024

Uttarakhand CM Pushkar Singh Dhami issues strong statement as bus plunges into gorge

Several people are feared dead as a 42-seater bus lost control and fell into a…

November 4, 2024

Say Goodbye to Wrinkles with the Power of Moringa

You are not the only one who wants to look perfect with glowing skiing, and…

November 4, 2024

This website uses cookies.

Read More